IL-28B / IFN-lambda-3 Protein & Antibody

Interleukin 28B / Interferon, lambda 3

IL-28B / IFN-lambda-3 Products

IL-28B / IFN-lambda-3 Protein, Recombinant

Molecule	Species	Description	Cat. No
IL-28B/IFN-lambda-3	Human	IL28B/IFN-lambda-3 Protein, Recombinant	11890-H08H

IL-28B / IFN-lambda-3 Antibody

Molecule	Application	Description	Cat. No
Human IL-28B /IFN-lambda-3	WB, ELISA	IL-28B / IFN-lambda-3 Antibody (Antigen Affinity Purified)	11890-RP02

  11890-H08H:

1. The EC₅₀ for this effect is typically 4-20 ng/mL. Measured in antiviral assays using WISH human amnion cells infected with vesicular stomatitis virus (VSV).

2. Immobilized human IL28B at 20µg/ml (100 µl/well) can bind human IL10RB with a linear ranger of 3.125-25 μg/ml. Measured by its binding ability in a functional ELISA.

IL-28B / IFN-lambda-3 Related Areas

Immunology>>Cytokine & Receptor>>Interleukin & Receptor>>IL-10/Interferon Family>>IL-28B/IFN-lambda-3

IL-28B / IFN-lambda-3 Alternative Names

IL-28B, IFN-lambda-3, IFNL3, IL28B, IL28C [Homo sapiens]

Il28b, IFN-lambda-3, IFL-1, INF-alpha, INF-lambda, Il28 [Mus musculus]

IL-28B / IFN-lambda-3 Background

Interleukin-28B (IL-28B) also known as Interferon lambda-3 and IFN-lambda-3, belongs to the type III interferon family of cytokines and are highly similar to IL-29. IL-28B belongs to the newly described interferon lambda (IFNλ) family of cytokines. IL-28B is a cytokine with immunomodulatory activity. It functions in Up-regulating MHC class I antigen expression. IL-28B displays potent antiviral activity and antitumor activity. This cytokine serves as ligand for the heterodimeric class II cytokine receptor composed of IL10RB and IL28RA. The ligand/receptor complex seems to signal through the Jak-STAT pathway. IL-28B, like IL-12, is capable of robustly enhancing adaptive immunity. Moreover, we describe for the first time how IL-28B reduces regulatory T-cell populations during DNA vaccination, whereas IL-12 increases this cellular subset. We also show that IL-28B, unlike IL-12, is able to increase the percentage of splenic CD8+ T cells in vaccinated animals, and that these cells are more granular and have higher antigen-specific cytolytic degranulation compared with cells taken from animals that received IL-12 as an adjuvant.

IL-28B / IFN-lambda-3 Related Studies

1. Ge D, et al.. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 461(7262): 399-401.
2. Morrow MP, et al.. (2009) Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood. 113(23): 5868-77.
3. Sheppard P, et al.. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 4(1): 63-8.